Tag Archives: Labiotech.eu

Join a clinical trial? The success rate of such trials is higher than you thought, but still awfully low overall; especially for Alzheimer’s.

The News: Instead of less than 10% of drugs reaching the market, a new study has found that almost 15% of new compounds pass clinical trial–which still suggests that it’s… Read more »

Investor Alert: Qiagen grabs Spanish biotech STAT-Dx in quest for new and better diagnostic tests. My personal take.

The News: Molecular diagnostics company Qiagen NV (Hilden DEU) has agreed to acquire biotech STAT-Dx SL (Barcelona) for up to €153 million–over 3 times the total funding the Spanish company has raised… Read more »

Ablynx soars 60% on Novo’s latest hostile bid; grab a piece of this Belgian biotech because the real action’s just starting.

The News: Denmark’s Novo Nordisk A/S (Copenhagen), the world’s biggest insulin maker, went public Monday (January 8, 2018) with a €2.6-billion ($3.1 billion) bid for Belgian biotech group Ablynx NV… Read more »

French nanocap Sensorion inks deal with Aussie implant-maker Cochlear for €1.6M capital infusion, R&D collaboration. Pearl by the Mediterranean?

The News: Sensorion SA (Montpellier FRA), a tiny biotech company pioneering novel treatments for inner-ear diseases, and Cochlear Ltd. (Sydney), the global leader in implantable hearing devices, in a joint… Read more »

London-based biotech TopiVert, although invisible, intends to shake up Allergan, Shire in the huge dry-eye space.

The News: TopiVert Pharma Ltd., a clinical-stage biotechnology company developing narrow spectrum kinase inhibitors (NSKIs) for chronic inflammatory gastrointestinal (GI) and ocular diseases, has announced results from a Phase 1/2a… Read more »

Netherlands-based, emerging biotech star arGEN-X gives shareholders two doses of great news; stock skyrockets.

The News: arGEN-X SE (Breda NLD) has smoked its target of $150 million for a US stock offering, which will support its cancer and autoimmune disease antibodies through the clinical phases…. Read more »

Micro biotech Alzinova, hiding out in southwest Sweden, using proprietary peptide technology that targets key Alzheimer’s toxins.

Background: Alzinova AB (Gothenburg) is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease (AD). The company was founded in 2011… Read more »

From across the pond, 2017’s brightest European biotech stars; perhaps under US’s radar, but still ready to soar?

Many said good riddance to 2016 for biotech and pharma; things could only get better this year–and the European industry didn’t disappoint, says Labiotech.eu, the quintessential industry observer and news… Read more »

Tiny Scottish biotech TauRx lobs bomb into Alzheimer’s fracas with Phase 3 success.

The News: After countless failures, the race for a treatment saw obscure TauRx Therapeutics Ltd. (Aberdeen Scotland) sprint ahead as its Alzheimer’s drug candidate prevented the formation of Tau tangles that… Read more »